Genelabs Technologies, Inc. to Present at Investment Conference

Apr 04, 2001, 01:00 ET from Genelabs Technologies, Inc.

    REDWOOD CITY, Calif., April 4 /PRNewswire/ --
 Genelabs Technologies, Inc. (Nasdaq:   GNLB) today announced that the company
 will present at the Tucker Anthony Sutro Health Care Conference in
 Laguna Niguel on April 5, 2001.  Matthew M. Loar, Vice President, Finance,
 will speak beginning at 9:50 am PDT.  The presentation is available to the
 public via the Internet through a live audio webcast.  Interested investors
 can access the presentation from the Genelabs Technologies web site:
 www.genelabs.com and the presentation will remain available through
 April 9, 2001.
     (Photo:  http://www.newscom.com/cgi-bin/prnh/19990728/GNLBLOGO )
     Genelabs Technologies, Inc., is a biopharmaceutical company engaged in the
 discovery and development of pharmaceutical products that target DNA. Apart
 from its research, the company is developing Aslera(TM) for systemic lupus
 erythematosus under a license from Stanford University.
     Genelabs' press releases are available at Genelabs' web site at
 www.genelabs.com.  In addition, press releases are available by fax, 24 hours
 a day at no charge, through PR Newswire's Company On-Call fax service at
 800-758-5804, extension 115419 and at www.prnewswire.com.
 
     CONTACT:  Matthew M. Loar, Vice President, Finance of Genelabs
 Technologies, Inc., 650-562-1424.
 
 

SOURCE Genelabs Technologies, Inc.
    REDWOOD CITY, Calif., April 4 /PRNewswire/ --
 Genelabs Technologies, Inc. (Nasdaq:   GNLB) today announced that the company
 will present at the Tucker Anthony Sutro Health Care Conference in
 Laguna Niguel on April 5, 2001.  Matthew M. Loar, Vice President, Finance,
 will speak beginning at 9:50 am PDT.  The presentation is available to the
 public via the Internet through a live audio webcast.  Interested investors
 can access the presentation from the Genelabs Technologies web site:
 www.genelabs.com and the presentation will remain available through
 April 9, 2001.
     (Photo:  http://www.newscom.com/cgi-bin/prnh/19990728/GNLBLOGO )
     Genelabs Technologies, Inc., is a biopharmaceutical company engaged in the
 discovery and development of pharmaceutical products that target DNA. Apart
 from its research, the company is developing Aslera(TM) for systemic lupus
 erythematosus under a license from Stanford University.
     Genelabs' press releases are available at Genelabs' web site at
 www.genelabs.com.  In addition, press releases are available by fax, 24 hours
 a day at no charge, through PR Newswire's Company On-Call fax service at
 800-758-5804, extension 115419 and at www.prnewswire.com.
 
     CONTACT:  Matthew M. Loar, Vice President, Finance of Genelabs
 Technologies, Inc., 650-562-1424.
 
 SOURCE  Genelabs Technologies, Inc.